YMAB•benzinga•
Oppenheimer Maintains Outperform on Y-mAbs Therapeutics, Lowers Price Target to $15
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 29, 2025 by benzinga